Fabian Schmidt

Fabian Schmidt

Auto-generated profile, based on publicly available information

Fabian Schmidt

Affiliation Biomedical Sciences Division (BioMed), King Abdullah University of Science and Technology (KAUST), Thuwal, Saudi Arabia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 October 2020 in eLife
Verified
Journal Article
Open access
YWYiska Weisblum
Yiska Weisblum
FSFabian Schmidt
Fabian Schmidt
FZFengwen Zhang
Fengwen Zhang
JDJustin DaSilva
Justin DaSilva
DPDaniel Poston
Daniel Poston
PBPaul D Bieniasz
Paul D Bieniasz
Neutralizing antibodies elicited by prior infection or vaccination are likely to be key for future protection of individuals and populations against SARS-CoV-2. Moreover, passively administered antibodies are among the most promising therapeutic and prophylactic anti-SARS-CoV-2 agents. However, the degree to which SARS-CoV-2 will adapt to evade neutralizing antibodies is unclear. Using a recombinant chimeric VSV/SARS-CoV-2 reporter virus, we show that functional SARS-CoV-2 S protein variants with mutations in the receptor-binding domain (RBD) and N-terminal domain that confer resistance to monoclonal antibodies or convalescent plasma can be readily selected. Notably, SARS-CoV-2 S variants that resist commonly elicited neutralizing antibodies are now present at low frequencies in circulating SARS-CoV-2 populations. Finally, the emergence of antibody-resistant SARS-CoV-2 variants that might limit the therapeutic usefulness of monoclonal antibodies can be mitigated by the use of antibody combinations that target distinct neutralizing epitopes.

21 July 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
FSFabian Schmidt
Fabian Schmidt
YWYiska Weisblum
Yiska Weisblum
FMFrauke Mücksch
Frauke Mücksch
HHHans-Heinrich Hoffmann
Hans-Heinrich Hoffmann
EMEleftherios Michailidis
Eleftherios Michailidis
PBPaul D. Bieniasz
Paul D. Bieniasz
The emergence of SARS-CoV-2 and the ensuing explosive epidemic of COVID-19 disease has generated a need for assays to rapidly and conveniently measure the antiviral activity of SARS-CoV-2–specific antibodies. Here, we describe a collection of approaches based on SARS-CoV-2 spike-pseudotyped, single-cycle, replication-defective human immunodeficiency virus type-1 (HIV-1), and vesicular stomatitis virus (VSV), as well as a replication-competent VSV/SARS-CoV-2 chimeric virus. While each surrogate virus exhibited subtle differences in the sensitivity with which neutralizing activity was detected, the neutralizing activity of both convalescent plasma and human monoclonal antibodies measured using each virus correlated quantitatively with neutralizing activity measured using an authentic SARS-CoV-2 neutralization assay. The assays described herein are adaptable to high throughput and are useful tools in the evaluation of serologic immunity conferred by vaccination or prior SARS-CoV-2 infection, as well as the potency of convalescent plasma or human monoclonal antibodies.

19 November 2020 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ASAlexandra Schaefer
Alexandra Schaefer
FMFrauke Mücksch
Frauke Mücksch
JLJulio C.C. Lorenzi
Julio C.C. Lorenzi
SLSarah R. Leist
Sarah R. Leist
MCMelissa Cipolla
Melissa Cipolla
TSTimothy Sheahan
Timothy Sheahan
SARS-CoV-2, the causative agent of COVID-19, has been responsible for over 42 million infections and 1 million deaths since its emergence in December 2019. There are few therapeutic options and no approved vaccines. Here, we examine the properties of highly potent human monoclonal antibodies (hu-mAbs) in a Syrian hamster model of SARS-CoV-2 and in a mouse-adapted model of SARS-CoV-2 infection (SARS-CoV-2 MA). Antibody combinations were effective for prevention and in therapy when administered early. However, in vitro antibody neutralization potency did not uniformly correlate with in vivo protection, and some hu-mAbs were more protective in combination in vivo. Analysis of antibody Fc regions revealed that binding to activating Fc receptors contributes to optimal protection against SARS-CoV-2 MA. The data indicate that intact effector function can affect hu-mAb protective activity and that in vivo testing is required to establish optimal hu-mAb combinations for COVID-19 prevention.

26 November 2021 in Science
Verified
Journal Article
Open access
IRInna Ricardo-Lax
Inna Ricardo-Lax
JLJoseph M. Luna
Joseph M. Luna
TTTran Thi Nhu Thao
Tran Thi Nhu Thao
JPJérémie Le Pen
Jérémie Le Pen
YYYingpu Yu
Yingpu Yu
CRCharles Rice
Charles Rice
A tool to study SARS-CoV-2: Work with infectious severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) requires high-level biocontainment facilities, making it important to develop safer molecular tools that can potentially be used under less stringent conditions. Self-replicating RNAs known as replicons have long been used to study pathogenic RNA viruses; however, developing replicons to study SARS-SoV-2 has been challenging because of its large genome. Ricardo-Lax et al . used a yeast-based system to construct SARS-CoV-2 replicons that cannot assemble infectious virus because they lack the spike protein required for host cell entry. Transfecting cells with a spike-expressing plasmid and separately with the replicon generates replicon delivery particles (RDPs) that are only capable of one cycle of infection. The replicons and the RDPs can be used in different contexts for drug screening, and viral assays. —VV

23 September 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ZWZijun Wang
Zijun Wang
PZPengcheng Zhou
Pengcheng Zhou
FMFrauke Mücksch
Frauke Mücksch
ACAlice Cho
Alice Cho
TTTarek Ben Tanfous
Tarek Ben Tanfous
MNMichel C. Nussenzweig
Michel C. Nussenzweig
Individuals who receive a third mRNA vaccine dose show enhanced protection against severe COVID-19, but little is known about the impact of breakthrough infections on memory responses. Here, we examine the memory antibodies that develop after a third or fourth antigenic exposure by Delta or Omicron BA.1 infection, respectively. A third exposure to antigen by Delta breakthrough increases the number of memory B cells that produce antibodies with comparable potency and breadth to a third mRNA vaccine dose. A fourth antigenic exposure with Omicron BA.1 infection increased variant-specific plasma antibody and memory B cell responses. However, the fourth exposure did not increase the overall frequency of memory B cells or their general potency or breadth compared to a third mRNA vaccine dose. In conclusion, a third antigenic exposure by Delta infection elicits strain-specific memory responses and increases in the overall potency and breadth of the memory B cells. In contrast, the effects of a fourth antigenic exposure with Omicron BA.1 are limited to increased strain-specific memory with little effect on the potency or breadth of memory B cell antibodies. The results suggest that the effect of strain-specific boosting on memory B cell compartment may be limited.

1 July 2022 in Journal of Experimental Medicine
Verified
Journal Article
Open access
PDF file
ACAlice Cho
Alice Cho
FMFrauke Mücksch
Frauke Mücksch
ZWZijun Wang
Zijun Wang
TTTarek Ben Tanfous
Tarek Ben Tanfous
JDJustin DaSilva
Justin DaSilva
MNMichel C. Nussenzweig
Michel C. Nussenzweig
The single-dose Ad.26.COV.2 (Janssen) vaccine elicits lower levels of neutralizing antibodies and shows more limited efficacy in protection against infection than either of the two available mRNA vaccines. In addition, Ad.26.COV.2 has been less effective in protection against severe disease during the Omicron surge. Here, we examined the memory B cell response to single-dose Ad.26.COV.2 vaccination. Compared with mRNA vaccines, Ad.26.COV.2 recipients had significantly lower numbers of RBD-specific memory B cells 1.5 or 6 mo after vaccination. Despite the lower numbers, the overall quality of the memory B cell responses appears to be similar, such that memory antibodies elicited by both vaccine types show comparable neutralizing potency against SARS-CoV-2 Wuhan-Hu-1, Delta, and Omicron BA.1 variants. The data help explain why boosting Ad.26.COV.2 vaccine recipients with mRNA vaccines is effective and why the Ad26.COV2.S vaccine can maintain some protective efficacy against severe disease during the Omicron surge.